![Granules Sitagliptin Phosphate](https://www.pharmacompass.com/image/flap/granules-sitagliptin-phosphate-desktop-headergif-87567.gif)
![Granules Sitagliptin Phosphate](https://www.pharmacompass.com/image/flap/granules-sitagliptin-phosphate-mobgif-61886.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercepharma.com/pharma/novo-nordisks-ozempic-answer-alzheimers-disease-study-indicates-it-lowers-risk-dementia
https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-reports-positive-pre-clinical-safety-data-of-da-1241-in-combination-with-sitagliptin-and-opens-enrollment-for-part-2-of-its-phase-2a-clinical-trial-evaluating-da-1241-for-the-treatment-of-mash-302037445.html
https://www.prnewswire.com/news-releases/zydus-receives-usfda-approval-for-zituvio-to-treat-adult-patients-with-type-2-diabetes-mellitus-301963298.html
https://endpts.com/merck-viatris-agree-to-settle-patent-feud-surrounding-diabetes-drugs/
https://www.financialexpress.com/healthcare/pharma-healthcare/pharma-companies-are-launching-generics-of-sitagliptin-post-patent-expiry-can-this-make-diabetic-care-affordable/2927237/
https://theprint.in/economy/govt-launches-diabetes-drug-sitagliptin-its-combinations-at-rs-60-pack-of-10/1131187/
https://www.merck.com/news/u-s-district-court-rules-in-favor-of-merck-in-sitagliptin-phosphate-patent-lawsuit/
https://endpts.com/to-avoid-shortage-of-mercks-diabetes-drug-fda-allows-higher-impurity-levels-temporarily/
https://www.fiercepharma.com/manufacturing/fda-angles-avert-shortage-mercks-diabetes-med-januvia-after-testing-flags-possible
https://health.economictimes.indiatimes.com/news/pharma/cadila-launches-generic-versions-of-type-2-diabetes-drug-sitagliptin-in-india/93276193
https://health.economictimes.indiatimes.com/news/pharma/glenmark-launches-sitagliptin-for-adults-with-type-2-diabetes-/92720256
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-13-2022-1649826529.pdf
https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-mylan
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214054
https://www.globenewswire.com/news-release/2021/09/09/2294779/24825/en/Codexis-and-Merck-Amend-and-Extend-Supply-Agreement-for-Enzyme-Used-in-Manufacture-of-Sitagliptin.html
https://www.expresspharma.in/unichem-labs-gets-tentative-us-fda-approval-for-sitagliptin-tablets-usp/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214784
https://www.fda.gov/drugs/drug-safety-and-availability/new-studies-show-diabetes-drug-not-proven-improve-blood-sugar-control-pediatric-patients
http://www.pharmafile.com/news/537725/diabetes-drug-could-increase-stem-cells-womb-treat-recurrent-miscarriage
http://www.pharmafile.com/news/537725/diabetes-drug-could-increase-stem-cells-womb-treat-recurrent-miscarriage
http://www.pharmafile.com/news/537725/diabetes-drug-could-increase-stem-cells-womb-treat-recurrent-miscarriage
https://www.reuters.com/article/us-novo-nordisk-strategy/novo-nordisk-targets-bigger-slice-of-diabetes-market-with-new-tablet-idUSKBN1W817O
https://endpts.com/here-comes-the-oral-glp-1-drug-for-diabetes-but-novo-nordisk-isnt-disclosing-rybelsus-pricing-just-yet/
http://www.pharmatimes.com/news/oral_semaglutide_trumps_jardiance,_januvia,_victoza_in_type_ii_diabetes_1302027
https://www.clinicaltrialsarena.com/news/novo-nordisk-oral-semaglutide/
https://www.fiercepharma.com/pharma/pharma-shares-slide-after-democrats-aggressive-drug-pricing-plan-leaks
https://www.fiercepharma.com/pharma/merck-scores-zerbaxa-label-expansion-years-after-cubist-buyout
http://www.pharmatimes.com/news/novo_nordisk_files_for_eu_approval_of_ozempic_in_type_ii_diabetes_1285844
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209573
https://www.fiercepharma.com/pharma/diabetes-meds-coverage-improves-but-novo-s-oral-semaglutide-could-disrupt-them-all-analyst
https://www.pharmacompass.com/pdf/news/janumet-metformin-hydrochloride-sitagliptin-phosphate-merck-vs-sandoz-1550294949.pdf
https://www.pharmacompass.com/pdf/news/janumet-xr-metformin-hcl-sitagliptin-phosphate-merck-vs-alvogen-pb-1550298178.pdf
https://www.pharmacompass.com/pdf/news/janumet-xr-metformin-hcl-sitagliptin-phosphate-merck-v-anchen-pharm-1550300435.pdf
https://www.pharmacompass.com/pdf/news/janumet-metformin-hydrochloride-sitagliptin-phosphate-merck-v-apotex-1550300246.pdf
https://health.economictimes.indiatimes.com/news/industry/fda-raids-traders-diverting-drugs-meant-for-defence/67860628
https://finance.yahoo.com/news/merck-3q-earnings-snapshot-105635748.html
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/list-centrally-authorised-products-requiring-notification-change-update-annexes_en-0.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208186
https://www.fiercepharma.com/marketing/merck-s-latest-digital-diabetes-coaching-platform-looks-to-fill-patient-education-and
http://www.pharmatimes.com/news/novos_oral_semaglutide_hits_targets_in_diabetics_with_renal_impairment_1249700
https://www.fiercepharma.com/marketing/novo-scores-another-semaglutide-win-time-kidney-impaired-patients